Enhanced tumor radiosensitivity by a survivin dominant-negative mutant

Oncology Reports

Volumn 23, Issue 1, 2010, Pages 97-103

  Yuan, Qing Zhong ^a,b   Wang, Chun Ting ^a   Mao, Yong Qiu ^a   Zhang, Peng ^c   Shi, Hua Shan ^a   Li, Zhi Yong ^a   Pan, Li ^a   Yu, Dan Dan ^a   Leng, Fei ^a   Chen, Xiang ^a   Ying, Wei ^c   Xu, Jing Hui ^c   Li, Wei ^c   Wu, Fan ^c   Wen, Yuan ^a   Ma, Tian Tai ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

^b No 313 Hospital of PLA   (China)

^c SICHUAN CANCER HOSPITAL   (China)

Author keywords

Anti angiogenic therapy; Apoptosis; Radiosensitivity; Survivin; Tumor

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE CHOLESTEROL LIPOSOME CONJUGATE; CD31 ANTIGEN; LIPOSOME; PLASMID DNA; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER RADIOTHERAPY; COMPLEX FORMATION; CONTROLLED STUDY; FEMALE; GENETIC CODE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; LEWIS CARCINOMA; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; TUMOR CELL; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD31; APOPTOSIS; CARCINOMA, LEWIS LUNG; CHOLESTEROL; COMBINED MODALITY THERAPY; FATTY ACIDS, MONOUNSATURATED; GENES, DOMINANT; LIPOSOMES; MICE; MICE, INBRED C57BL; MICROTUBULE-ASSOCIATED PROTEINS; PLASMIDS; QUATERNARY AMMONIUM COMPOUNDS; RADIATION TOLERANCE; RADIOTHERAPY; TETRAZOLIUM SALTS; THIAZOLES;

EID: 76049124188     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000610     Document Type: Article

References (50)

1. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M and Tanigawa N: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6: 127-134, 2000.
2. Miller M, Smith D, Windsor A and Kessling A: Survivin gene expression and prognosis in recurrent colorectal cancer. Gut 48: 137-138, 2001.
3. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF and Guillou PJ: Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 86: 886-892, 2002.
4. Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D and Watanabe N: Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 91: 1204-1209, 2000.
5. Colella G, Zaffaroni N, Pennati M, Benini E and Daidone MG: Expression of the anti-apoptosis gene survivin correlates with taxol resistance in human ovarian cancer. Proc Am Assoc Cancer Res 42: 302, 2001.
6. Ling X, Bernacki RJ, Brattain MG and Li F: Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem 279: 15196-15203, 2004.
7. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Cancer Rev 3: 46-54, 2003.
8. Pennati M, Folini M and Zaffaroni N: Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 28: 1133-1139, 2007.
9. Kanwar JR, Shen WP, Kanwar RK, Berg RW and Krissansen GW: Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 93: 1541-1552, 2001.
10. Pennati M, Colella G, Folini M, Citti L, Daidone MG and Zaffaroni N: Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Invest 109: 285-286, 2002.
11. Paduano F, Villa R, Pennati M, Folini M, Binda M, Daidone MG and Zaffaroni N: Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17- demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther 5: 179-186, 2006.
12. Jiang G, Li J, Zeng Z and Xian L: Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma. Cancer Biol Ther 5: 435-440, 2006.
13. Pisarev V, Yu B, Salup R, Sherman S and Gabrilovich DI: Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 9: 6523-6533, 2003.
14. Grossman D, Kim PJ, Schechner JS and Altieri DC: Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 98: 635-640, 2001.
15. McKay TR, Bell S, Tenev T, Stoll V, Lopes R, Lemoine NR and McNeish IA: Procaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategy. Oncogene 22: 3539-3547, 2003.
16. Peng XC, Yang L, Wei YQ, et al: Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34→Ala mutant. J Exp Clin Cancer Res 27: 46, 2008.
17. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD and Pavlakis GN: Improved DNA:liposome complexes for increased systemic delivery and gene expression. Nat Biotech 15: 647-652, 1997.
18. Lin X, Chen X, Zhao X, et al: Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice. Gynecol Oncol 104: 540-546, 2007.
19. Owen JB, Coia LR and Hanks GE: Recent patterns of growth in radiation therapy facilities in the United States: a patterns of care study report. Int J Radiat Oncol Biol Phys 24: 983-986, 1992.
20. Jung M and Dritschilo A: Signal transduction and cellular responses to ionizing radiation. Semin Radiat Oncol 6: 268-272, 1996.
21. Zhivotovsky B, Joseph B and Orrenius S: Tumor radio-sensitivity and apoptosis. Exp Cell Res 248: 10-17, 1999.
22. Zaffaroni N and Daidone MG: Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resistance Updates 5: 65-72, 2002.
23. Vaux DL and Korsmeyer SJ: Cell death in development. Cell 96: 245-254, 1999.
24. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
25. Baierlein SA, Distel L, Sieber R, Weiss C, Rödel C, Sauer R and Rödel F: Combined effect of tumor necrosis factor-alpha and ionizing radiation on the induction of apoptosis in 5637 bladder carcinoma cells. Strahlenther Onkol 182: 467-472, 2006.
26. Weiss C, Rödel F, Wolf I, et al: Combined-modality treatment and organ preservation in bladder cancer. Do molecular markers predict outcome? Strahlenther Onkol 181: 213-222, 2005.
27. Nakano K and Vousden KH: PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7: 683-694, 2001.
28. Oda E, Ohki R, Murasawa H, et al: Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288: 1053-1058, 2000.
29. Wei MC, Zong WX, Cheng EH, et al: Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292: 727-730, 2001.
30. Haimovitz-Friedman A, Kan CC, Ehleiter D, Persaud RS, McLoughlin M, Fuks Z and Kolesnick RN: Ionizing radiation acts on cellularmembranes to generate ceramide and initiate apoptosis. J Exp Med 180: 525-535, 1994.
31. Cryns V and Yuan Y: Proteases to die for. Genes Dev 12: 1551-1570, 1999.
32. Thornberry NA and Lazebnik Y: Caspases: enemies within. Science 281: 1312-1316, 1998.
33. Deveraux QL and Reed JC: IAP family proteins: suppressors of apoptosis. Genes Dev 13: 239-252, 1999.
34. Sun C, Cai M, Gunasekera AH, et al: NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP. Nature 401: 818-822, 1999.
35. Shi Y: Survivin structure: crystal unclear. Nat Struct Biol 7: 620-623, 2000.
36. Du C, Fang M, Li Y, Li L and Wang X: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102: 33-42, 2000.
37. Suzuki A, Hayashida M, Ito T, et al: Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16 (INK4a) and Cdk2/cyclin E complex activation. Oncogene 19: 3225-3234, 2000.
38. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
39. O'Connor DS, Schechner JS, Adida C, et al: Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 156: 393-398, 2000.
40. Fuks Z and Kolesnick R: Engaging the vascular component of the tumor response. Cancer Cell 8: 89-91, 2005.
41. Marx J: Angiogenesis: a boost for tumor starvation. Science 301: 452-454, 2003.
42. Thomlinson RH and Gray LH: The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9: 539-549, 1955.
43. Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H and Song CW: Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res 62: 1702-1706, 2002.
44. Lee CG, Heijn M, di Tomaso E, et al: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60: 5565-5570, 2000.
45. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH and Augustin HG: Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60: 1388-1393, 2000.
46. Andersen MH and Thor SP: Survivin - a universal tumor antigen. Histol Histopathol 17: 669-675, 2002.
47. Rohayem J, Diestelkoetter P, Weigle B, et al: Antibody response to the tumor-associated inhibitor of apoptosis protein in cancer patients. Cancer Res 60: 1815-1817, 2000.
48. Schmidt SM, Schag K, Müller MR, et al: Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 102: 571-576, 2003.
49. Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, thor Straten P and Andersen MH: Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther 3: 173-179, 2004.
50. Xiang R, Mizutani N, Luo Y, et al: A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 65: 553-561, 2005.